Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Last trade$7.93
Day change+$0.095 (+1.21%)
Day range$7.82 – $8.20
Volume83,527
Market cap$173M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$172.58M
Price / earnings
—
Price / book
3.5×
Price / sales
8.55×
EV / sales
6.67×
EV / EBITDA
-4.5×
Profitability
Earnings per share
-$1.35
Return on assets
-46.47%
Return on equity
-60.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.13×
Quick ratio
6.34×
Cash ratio
4.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.84M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ACOG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$7.78M
$6.09M
$3.53M
$2.79M
$2.84M
$1.66M
$2.93M
$0
Cost of revenue
$482.42K
$391.06K
$271.78K
$252.25K
$633.45K
$203.86K
$836.54K
$0
Gross profit
$7.29M
$5.7M
$3.26M
$2.54M
$2.21M
$1.45M
$2.09M
$0
Selling, general and administrative
$12.38M
$11.45M
$10.26M
$9.89M
$5.11M
$9.49M
$5.09M
$1.63M
Research and development
$1.34M
$2.01M
$1.1M
$569.75K
$513.78K
$406.14K
$400.42K
$1.04M
Total operating expenses
$13.73M
$13.46M
$11.36M
$10.47M
$5.63M
$9.9M
$5.5M
$2.69M
Operating income
-$6.43M
-$7.76M
-$8.1M
-$7.93M
-$3.42M
-$8.45M
-$3.4M
-$2.69M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$7.62M
-$8.79M
-$6.48M
-$6.86M
$574.38K
-$13.2M
-$1.73M
-$5.81M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.62M
-$8.79M
-$6.48M
-$6.86M
$574.38K
-$13.2M
-$1.73M
-$5.81M
Net income attributable to common shareholders
-$7.62M
-$8.79M
-$6.48M
-$6.86M
$574.38K
-$13.2M
-$1.73M
-$5.81M
EBITDA
-$6.31M
-$7.65M
-$8.07M
-$7.9M
-$3.41M
-$8.44M
-$3.4M
-$2.67M
Basic earnings per share
-$0.35
-$0.40
-$0.30
-$0.30
$0.04
-$0.82
-$0.11
-$0.52
Diluted earnings per share
-$0.35
-$0.40
-$0.32
-$0.31
-$0.29
-$0.82
-$0.11
-$0.52
Recent news
Company coverage with links to the original publishers.
Wall Street analysts have set a mean price target of $18.2 for Alpha Cognition Inc. (ACOG), currently trading at $8.3, suggesting a potential 119.3% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.
Alpha Cognition Inc. (ACOG) reported a quarterly loss of $0.28 per share, beating the consensus estimate of $0.33 loss, with a 15.15% earnings surprise. The company posted revenues of $7.78 million, surpassing estimates by 9.04% and nearly tripling year-ago revenues of $2.84 million. The stock has gained 34.3% year-to-date, outperforming the S&P 500's 9.9% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Foghorn Therapeutics reported Q3 2026 earnings of $0.8 per share, significantly beating the consensus estimate of a loss of $0.23 per share, with a 447.83% earnings surprise. Revenues reached $83.54 million, vastly exceeding the consensus estimate by 974.37%. However, the stock has underperformed the market, declining 65.4% year-to-date compared to the S&P 500's 7.8% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Halozyme Therapeutics reported Q3 2026 earnings of $2.39 per share, beating consensus estimates of $2.29, with revenues of $492.97 million exceeding expectations by 2.27%. The stock has gained 93.7% year-to-date, significantly outperforming the S&P 500's 12.3% gain. However, the company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Urogen Pharma reported a quarterly loss of $0.03 per share, beating the consensus estimate of $0.05, with revenues of $89 million exceeding expectations by 2.73%. Despite the positive earnings surprise and 46.9% year-to-date stock gain, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release, suggesting near-term underperformance relative to the market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.